BioSpace News Archive

Cybin Inc. is pleased to announce a firm commitment underwritten offering (the “ Offering ”) of 66,666,667 units of the Company (the “ Units ”) to one of the Company’s largest existing institutional shareholders and new institutional investors at a price of US$0.45 per Unit for gross proceeds of approximately US$30 million.

Resonant, a subsidiary of Renew Biotechnologies aimed at releasing novel diagnostics for neurodegenerative diseases, recently published research revealing a novel blood biomarker of neurodegeneration.

Assembly Biosciences, Inc. announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the company granted non-statutory stock options to a new employee.

Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023.

Boston Pharmaceuticals today announced new data supporting BOS-580, its investigational, long-acting fibroblast growth factor 21 (FGF21) analog for the treatment of non-alcoholic steatohepatitis (NASH). Results support a once-monthly dosing schedule for BOS-580 and the positive effects of treatment for people living with NASH who are at risk for or have type 2 diabetes.

ReCode Therapeutics today announced that company management will participate in the upcoming November conferences.

Immunome, Inc. today announced that Clay Siegall, PhD, President and CEO of Immunome, will present at the Stifel 2023 Healthcare Conference on Wednesday, November 15, at 3:00 p.m. ET.

Biotricity Inc. (Nasdaq:BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor sector of consumer healthcare, announced that it will host its Second Quarter Fiscal Year 2024 Financial Results and Business Update Call on Tuesday, November 14, 2023.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.